Detalhe da pesquisa
1.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med
; 383(9): 825-835, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846061
2.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846060
3.
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation.
Cancer Discov
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691346
4.
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.
Proc Natl Acad Sci U S A
; 107(43): 18392-7, 2010 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20930119
5.
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Cancer Discov
; 13(8): 1789-1801, 2023 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269335
6.
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Clin Cancer Res
; 28(12): 2517-2526, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302585
7.
Modeling oncogene addiction using RNA interference.
Proc Natl Acad Sci U S A
; 105(34): 12480-4, 2008 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18711136
8.
Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.
Proc Natl Acad Sci U S A
; 105(27): 9284-9, 2008 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-18591665
9.
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Clin Cancer Res
; 27(1): 34-42, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082208
10.
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Proc Natl Acad Sci U S A
; 104(50): 19936-41, 2007 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18077425
11.
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma.
Thyroid
; 30(9): 1384-1389, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292131
12.
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
J Thorac Oncol
; 15(4): 541-549, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31988000
13.
A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.
Thyroid
; 29(11): 1704-1707, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31650892
14.
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Cancer Discov
; 7(9): 963-972, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578312
15.
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036231
16.
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Clin Lung Cancer
; 22(3): e442-e445, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32660930
17.
Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Clin Cancer Res
; 21(5): 1028-35, 2015 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25549723
18.
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32923911
19.
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
Elife
; 42015 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25686219
20.
Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.
Head Neck
; 36(8): 1181-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23852799